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Infections caused by parasites in humans represent one of the main public health concerns. Amoebiasis, a parasitic infection
caused by Entamoeba histolytica (E. histolytica), is considered endemic in Mexico, where Argemone mexicana (A. mexicana) has
been used in traditional medicine to treat intestinal parasitic diseases. ,e objective of this work was to evaluate the potential
biological activity of A. mexicana on E. histolytica. For this purpose, a methanolic extract was prepared from A. mexicana leaves,
and a differential fractionation was carried out with solvents of different polarities. ,e inhibitory capacities of the extract and its
fractions were evaluated in vitro using HM1-IMSS, a strain of Entamoeba histolytica. A. mexicana extract was found to have
a growth-inhibiting activity for E. histolytica, showing IC50 � 78.39 μg/mL.,e extract was characterized phytochemically, and the
methanolic extract fractions were analyzed by liquid chromatography (HPLC) and mass spectrometry (MS). Berberine and
jatrorrhizine were present in the active fractions, and these compounds may be responsible for the antiparasitic activity. ,e
identification of amoebicidal activity of A. mexicana on E. histolytica gives support to the traditional use. Further studies with
berberine and jatrorrhizine will be carried out to understand the mechanism involved.
1. Introduction
Parasitosis represents a global health problem, with in-
testinal parasites being one of the main causes of morbidity.
,is type of disease is closely linked to poverty and poor
hygienic and sanitary conditions, so it appears more fre-
quently in developing countries, especially in geographical
areas where the ecological conditions favor the persistence of
parasite [1]. E. histolytica is one of the most common parasites
and is the causative agent of human amoebiasis. Infections
with this parasite have different clinical manifestations,
including diarrhea, dysentery, and liver abscess. Amoebiasis is
acquired by ingesting E. histolytica cysts in contaminated food
or water. ,is disease is a major health problem, according to
the Global Burden of Disease Study conducted in 2013 [2].
Approximately 50 million people are affected by E. histolytica
each year, and of these, approximately 100,000 die [3]. In fact,
intestinal infections by protozoa, such as amoebiasis, are the
third leading cause of death in the world.
,e drug of first choice for treating amoebiasis is met-
ronidazole, which interacts with theDNAof the protozoan [4],
causing a loss of the helical structure and inhibiting the
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synthesis of nucleic acids, ultimately resulting in cell death
[5–7]. ,e therapeutic use of natural products is as old as
human civilization, and the vastmajority of people on the planet
continue to rely on the therapeutic properties of plants. In
addition, the search for active ingredients frommedicinal plants
continues to provide active ingredients for treating diseases [2].
,e exploitation of this potential source of medicines requires
ethnobotanical, ethnopharmacological, chemical, biological,
pharmacological, and toxicological studies [8].
Argemone mexicana L. (Papaveraceae), also known as
Mexican poppy, has a wide distribution in many tropical and
subtropical countries [9], and it is common to find it on the
edges of roads, in vacant lots and on the sides of train tracks.
Various types of chemical constituents are present in this plant,
although alkaloids are the most abundant [10]. In traditional
medicine, different parts of this plant are used to treat chronic
skin diseases, ulcers, asthma, and other intestinal conditions
[11–13]. Studies have shown that the extracts of A. mexicana
and some of its individual components are effective against
bacteria, fungi, viruses, nematodes, and parasites [14–18].
Considering the properties and background of this plant
in relation to different microorganisms as well as the ease of
obtaining the plant, the main objective of this study was to
evaluate the activity of the methanolic extract of leaves of A.
mexicana in vitro against E. histolytica HM1-IMSS and to
identify the components present in the fractions of the
extract because E. Histolytica represents one of the main
etiological agents worldwide.
2. Materials and Methods
2.1. Vegetal Material. ,e leaves of A. mexicana were col-
lected in the city of Monterrey, Nuevo Leo´n, Mexico, in
February 2017.,ematerial was identified asA. mexicana by
the Department of Botany of the Faculty of Biological
Sciences of the Autonomous University of Nuevo Leo´n. A
voucher specimen was deposited with voucher no. 1208882
in the Herbarium of the Faculty.
2.2. Extraction. To obtain the methanolic extract of A.
mexicana, the leaves were dried at room temperature and
subjected to extraction by maceration [19]. For this, a 100 g
portion was milled to a fine powder, and successive ex-
tractions (5× 250mL) were made with absolute methanol
(Sigma Chemical Co., St. Louis, MO, USA) on an orbital
shaker (Lab-line, 3508, Lab-line Instruments Inc., Melrose
Park, IL, USA) at room temperature (24 h each). ,e ob-
tained extract was filtered with Whatman no. 1 paper and
concentrated under reduced pressure at 45°C using a rotary
evaporator (Heidolph Rotary Evaporator, Laborota 4003,
Heidolph Instruments GmbH & Co KG, Germany). ,en,
the residual solvent was evaporated at room temperature.
,e solid extract obtained was weighed to calculate the yield
percentage and stored at 4°C until further use.
2.3. Fractionation of the Methanol Extract of A. mexicana.
Serial partitions of the solid extract were made using solvents
of different polarities and reactivity rates (Merck KGaA,
Darmstadt, Germany). In the first stage, an extraction with
hexane (3×100 L) was carried out, and the extracts were
mixed and filtered with Whatman no. 1 paper (fraction A).
,e residue was extracted with 3 portions of 100mL of
CHCl3 (fraction B) and filtered again with Whatman paper,
and the residual solid absolute MeOH (4×100mL) was
extracted and filtered with Whatman no. 1 (fraction C).
,en, 100mL of methanol was added to the solid and
subjected to heating (120°C) for 5min with stirring, followed
by filtration (fraction D). Finally, the resulting solid was
solubilized with water (fraction E).
2.4. 7e Activity of the Methanol Extract of A. mexicana
against E. histolytica. ,e antiprotozoal activity of the ex-
tract was carried out with the microassay technique as
previously described [7]. In brief, a concentrated solution of
crude methanolic extract and another of berberine
(1mg/mL) in dimethyl sulfoxide (DMSO) at 5% v/v were
prepared. ,is solution was sterilized by passing through
a nylon membrane filter with a 0.22 μm pore size (Merck
Millipore, KGaA, Darmstadt, Germany) and stored, pro-
tected from light, at 4°C until use. Serial dilutions were
performed by taking 500 μL of the stock solution and adding
500 μL of sterile deionized water.,e concentrations of these
working solutions were 0.031, 0.062, 0.125, 0.25, and
0.5mg/mL. In culture tubes (Vial, Bellco Biotechnology,
Bellco Glass Inc., Vineland, NJ, USA) with 1mL of TYI-S33,
2×104 trophozoites of E. histolytica were deposited in the
log phase, and 50 μL of working solution was added to each
tube. ,e tubes were incubated at 36.6°C for 72 h. Metro-
nidazole at a concentration of 0.124 μg/mL was used as
a positive control, and 5% DMSO was used as a negative
control. All bioassays were performed in triplicate and re-
peated three times [20]. After the incubation period, the
tubes were cooled in ice water for 15min, and the number of
trophozoites per mL of each tube was counted with a he-
mocytometer (Neubauer, Hausser Scientific, Horsham, PA,
USA).
2.5. Statistical Analysis. Growth inhibition percentages were
estimated in reference to untreated controls. ,e extract
concentration that would inhibit in 50% the E. histolytica
growth, that is, IC50 with 95% confidence limits [21], was
calculated by probit analysis (SPSS 24.0, SPSS Inc., Chicago,
IL, USA).,e log dose (concentration) response relationship
was used in order to obtain the linear probit model. A chi-
square goodness of fit test was used for assessing probit
model adequacy.
2.6.PhytochemicalTests. To determine the functional groups
of the compounds present in the methanolic extract and its
active fractions, conventional chemical tests were carried out
[19]. ,ese tests included 2,4-dinitrophenylhydrazine (car-
bonyl group), anthrone (carbohydrates), Baljet (sesquiter-
pene lactones), sodium bicarbonate (carboxyl group), ferric
chloride (tannins), Dragendorff (alkaloids), Liebermann–
Burchard (sterols and triterpenes), potassium permanganate
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(double bonds), Shinoda (flavonoids), sodium hydroxide
(coumarins), Borntra¨ger (quinones), and sodium bicarbonate
(saponins).
2.7. HPLC Analysis andMass Spectrometry. Fractions C and
D were analyzed by HPLC and MS. To do so, 15mg of the
dry fractions were obtained, dissolved in 2mL of a mixture
of methanol-acetonitrile (50 : 50), and filtered through
a 0.2 μm nylon membrane (Millipore). For the analysis,
a Dionex Ultimate 3000 UHPLC System (,ermo Fisher,
Dreieich, Germany) with a UV-Vis detector and coupled to
an LCQ Fleet mass spectrometer (,ermo Scientific)
equipped with an electrospray ionization source and ion trap
analyzer were used.,e HPLC analysis was performed using
a Kinetex PFP column (50× 2.1m, Phenomenex, USA). As
the mobile phase, a mixture of an aqueous solution of formic
acid (1%) and methanol was used, starting with 30%
methanol and increasing linearly to 100% over 10min,
returning to the initial conditions in the 11th minute and
conditioning for 15min before the next injection. ,e
mobile phase flow was 200 μL/min, the column was main-
tained at 50°C, and the injection volume used was 0.1 μL.
Nitrogen was used at a flow of 40 units as a nebulization gas
(sheath gas). Ionization was performed in a positive mode.
,e electrospray capillary voltage used was 5 kV, the des-
olvation capillary voltage was 43V, and the temperature was
275°C.,e lens tube voltage was set at 75V. Data acquisition
was performed in full-scan mode at m/z 50 to 70 and with
mass/mass experiments used for the most intense ions in the
collision-induced dissociation (CID) mode, adjusting the
normalized collision energy to obtain an adequate frag-
mentation with an isolation width of 1m/z, an activation RF
voltage (activation Q) of 0.25, and an activation time of
30ms. All experiments were performed in triplicate.
2.8. Nuclear Magnetic Resonance Spectroscopy (NMR).
1H-NMR and 13C-NMR experiments were carried out using
a Bruker Avance III HD 400 (400MHz) spectrometer
equipped with gradients and a 5mm multinuclear probe
(Bruker Corp., Billerica, MA, USA). For analysis, 10mg of
berberine standard, the dried methanolic raw extract, and
fractions C and D were dissolved in methanol-d4 with 0.3%
TMS as a zero reference. NMR spectra were analyzed using
Topspin 3.0 software (Bruker Corp.)
3. Results and Discussion
,e yield of methanol extracted by macerating (41.2 g) the
dried leaf of A. mexicana was 9.95% p/p. As seen in Table 1,
the extract was positive for unsaturation, sterols, triterpenes,
quinones, tannins, saponins, carbohydrates, alkaloids, and
flavonoids. ,ese results coincide with those of previous
studies, which have reported the presence of terpenoids,
flavonoids, phenolics, long-chain aliphatic compounds, and
a few aromatic compounds that are other constituents of this
plant [8, 15]. However, it must be noted that the chemical
composition of the plant may differ according to the parts of
the plant that are used, the harvest season, and the geo-
graphical area.
Before evaluating the activity of the extract, it was
necessary to assess the growth kinetics of E. histolytica to
determine the logarithmic phase. Its generation time was
found to be 6.3 h, and its doubling time was 4.3 h. After 72 h,
the exponential phase begins, in which the parasite enters
a period characterized by cellular duplication and is in its
most active metabolic phase [22].
,e activity assays against E. histolytica showed the
ability of A. mexicana methanol extract to inhibit the tro-
phozoite growth of E. histolytica in in vitro cultures under
axenic conditions. As shown in Figure 1, the percentage of
inhibition increases with higher extract concentrations. In
addition, a negative control consisting of culture medium
with 5% DMSO was evaluated for how it dissolved the
extract inoculated with E. histolytica, and a positive control
consisting of culture medium, inoculum, and metronidazole
at 1 μg/mL as well as a blank control containing the culture
medium and inoculum was tested.
,e results showed a response behavior corresponding to
the dose: as the concentration of the extract increased, the
viability decreased. At a concentration of 500μg/mL, the in-
hibition was 96.6%. Even at the lowest test concentration of
15.6μg/mL, the extract still showed 8.8% inhibition. ,e
negative control and the inoculum control had no activity
against the parasite, but the positive control showed 99.6%
inhibition. ,e determination of the mean inhibitory con-
centration against trophozoites of E. histolytica by the probit
test showed that the methanolic extract had an IC50 of 78.39±
0.48μg/mL (Figure 2), berberine of 40.65± 1.23µg/mL, and
that metronidazole had an IC50 of 0.14± 0.02μg/mL. ,e
result of the probit analysis applied to these data gave a chi-
square value of 16,217 (P � 0.300), which justifies that the
data conform to the probit model, and the probit equations
were obtained for each repetition: P � −3.929 + 2.09(μg/mL),
P � −3.935 + 2.09(μg/mL), and P � −3.924 + 2.09(μg/mL),
highly significant results (P< 0.01).
Although there are no reports on the use of extracts of
A. mexicana against E histolytica, some studies have eval-
uated extracts of this plant against other parasites, such as
Table 1: Chemical tests of the methanol extract of Argemone
mexicana.
Phytochemical tests
KMnO4 (double bonds) +
2,4-dinitrophenylhydrazine (carbonyl group) −
NaOH (coumarins) −
Baljet (sesquiterpene lactones) −
Borntra¨ger (quinones) +
Liebermann–Burchard (sterols and triterpenes) +
NaHCO3 (carboxyl group) −
Ferric chloride (tannins) +
Saponins +
Shinoda (flavonoids) +
Anthrone (carbohydrates) +
Dragendorff (alkaloids) +−: negative; +: positive.
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nematodes [23]. ,e aqueous extract of leaves of A. mex-
icana exhibits significant anthelmintic activity against
Ascaridia galli at a concentration of 100 μg/mL, and this
aqueous extract has also been used as an anthelmintic
against the earthworm Pheritima posthuma [20]. Antipar-
asitic capacity against Plasmodium falciparum has also been
demonstrated [9, 24], as the aqueous extract of the aerial
parts of the plant exhibits activity against the chloroquine-
resistant strain, with an IC50 value of 5.89 μg/mL.
When the activity of the fractions of the methanolic
extract was evaluated against the parasite, it was found that,
at 125 μg/mL, fractions C and D presented lethality per-
centages of 72.39 and 79.09%, respectively. ,us, these
fractions were cataloged as active because the other fractions
showed no relevant activity against E. histolytica. ,e active
fractions (C and D) were analyzed by UHPLC-MS. Among
the compounds that were present in both fractions, two
important signals at m/z 336 and 338 were found and
MS/MS experiments were carried out. Fragmentation of ion
atm/z 336 yielded fragments atm/z 321, 320, and 292, while
product ions obtained for ion at m/z 338 were 323, 322, and
294. ,e MS/MS spectra are similar to those reported for
berberine and jatrorrhizine. As an example, Figure 3 shows
the chromatograms and corresponding mass spectra for
fraction D. In order to confirm the presence of the
abovementioned alkaloids, 1H-RMN and 13C-RMN analysis
were carried out for fractions C and D and the raw meth-
anolic extract. For instance, in Figure 4, a comparison be-
tween the RMN spectra obtained for berberine, fraction D,
and the raw methanolic extract is presented. As can be seen,
for both the extract and fraction D, it is possible to observe
the signals corresponding to berberine. ,e presence of
jatrorrhizine could not be confirmed with these experiments,
probably due to the low sensitivity of RMN, so further work
on the isolation of the chromatographic peak that produces
this signal will be made. ,ese results agree with previous
phytochemical investigations that revealed the presence of
several alkaloids [11], including berberine, jatrorrhizine,
protopine, allocryptopine, and sanguinarine. In addition, the
plant produces more than 25 benzylisoquinoline alkaloids
[25].
,e compounds found in fractions C and D are of the
alkaloid type and are probably responsible for the activity, as
their effectiveness has been shown in extracts from plants of
other genera that have been tested against the following
parasites: Giardia lamblia, Trichomonas vaginalis, and E.
histolytica [26]. Specifically, several pharmacological effects
and activity against a variety of bacteria, fungi, protozoa,
helminths, and viruses have been reported for berberine
[27]. It has been demonstrated that berberine possesses
inhibitory activity against G. lamblia and T. vaginalis, and in
axenic cultures, morphological changes have been observed
in the parasites by exposing these parasites to alkaloids,
which caused a grouping of the chromatin in the nucleus and
formation of autophagic vacuoles and aggregates of small
vacuoles in the cytoplasm [28]. Also, using animal models
such as the Syrian hamster, it has been shown that berberine
has an effect against promastigotes of Leishmania pan-
amensis and Leishmania major [29]. In addition, in a study
conducted in 2014 [30], the antileishmanial activity of
berberine against promastigotes of L. major and Leishmania
tropica was evaluated. ,e results revealed that berberine
was effective in inhibiting L. major and L. tropica pro-
mastigotes growth in a dose-dependent manner with IC50
values varying from 2.1 to 26.6 μg/mL.
By contrast, jatrorrhizine, whose presence should be
confirmed, is a protoberberinoid alkaloid and has been
found in different plant species such as Enantia chlorantha
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Figure 2: Probit graph of the activity of the methanol extract of A.
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Figure 1: Evaluation of the viability of trophozoites of E. histo-
lytica. Control: medium TYI-S33 inoculum of E. histolytica. Ctrl−:
negative control (DMSO 5% inoculum of E. histolytica). Ctrl+:
positive control (metronidazole 1 μg/mL). ,e error bars represent
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Figure 3: Chromatograms and mass spectra obtained for fraction D. LC-MS/MS fragmentogram and MS/MS spectra obtained for
(a) berberine (m/z 336) and (b) jatrorrhizine (m/z 338) in fraction D.
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Figure 4: Comparison of (a) 1H-NMR and (b) 13C-NMR spectra of berberine, fraction D, and raw methanolic extract.
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and A. mexicana [31]. It has been reported to have an anti-
inflammatory effect and may improve blood flow and mi-
totic activity in traumatized rat livers [32]. In addition, its
antimicrobial and antifungal activities have beedn reported
[17]. ,e activity of this alkaloid was also reported in vitro
against P. falciparum, Leishmania donovani, and Trypano-
soma brucei rhodesiense [32]. ,erefore, the results obtained
in this work validate the use of this plant as an antiamobic
agent. ,is study also contributes to the search for new
sources for the development of promising natural antipar-
asitic agents with possible applications in the pharmaceutical
industry. More studies are being done to identify the synergy
between the extract of the plant and standard antibiotics.
4. Conclusions
,e methanolic extract of the leaves of A. mexicana showed
growth inhibition activity against trophozoites of the E.
histolytica strain HM1 : IMSS under axenic conditions in
vitro. ,e analysis of the fractions of this extract by HPLC-
MS showed greater amoebicidal activity, thus indicating the
presence of berberine alkaloids and jatrorrhizine.
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